370 related articles for article (PubMed ID: 34341335)
21. Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech).
Korth J; Jahn M; Dorsch O; Anastasiou OE; Sorge-Hädicke B; Eisenberger U; Gäckler A; Dittmer U; Witzke O; Wilde B; Dolff S; Kribben A
Viruses; 2021 Apr; 13(5):. PubMed ID: 33923063
[TBL] [Abstract][Full Text] [Related]
22. Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine.
Terpos E; Trougakos IP; Apostolakou F; Charitaki I; Sklirou AD; Mavrianou N; Papanagnou ED; Liacos CI; Gumeni S; Rentziou G; Korompoki E; Papassotiriou I; Dimopoulos MA
Am J Hematol; 2021 Jul; 96(7):E257-E259. PubMed ID: 33837984
[No Abstract] [Full Text] [Related]
23. Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study.
Terpos E; Gavriatopoulou M; Fotiou D; Giatra C; Asimakopoulos I; Dimou M; Sklirou AD; Ntanasis-Stathopoulos I; Darmani I; Briasoulis A; Kastritis E; Angelopoulou M; Baltadakis I; Panayiotidis P; Trougakos IP; Vassilakopoulos TP; Pagoni M; Dimopoulos MA
Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503290
[TBL] [Abstract][Full Text] [Related]
24. Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine.
Gavriatopoulou M; Terpos E; Kastritis E; Briasoulis A; Gumeni S; Ntanasis-Stathopoulos I; Sklirou AD; Malandrakis P; Eleutherakis-Papaiakovou E; Migkou M; Trougakos IP; Dimopoulos MA
Clin Exp Med; 2022 May; 22(2):319-323. PubMed ID: 34283338
[TBL] [Abstract][Full Text] [Related]
25. Antibody titres decline 3-month post-vaccination with BNT162b2.
Favresse J; Bayart JL; Mullier F; Elsen M; Eucher C; Van Eeckhoudt S; Roy T; Wieers G; Laurent C; Dogné JM; Closset M; Douxfils J
Emerg Microbes Infect; 2021 Dec; 10(1):1495-1498. PubMed ID: 34232116
[TBL] [Abstract][Full Text] [Related]
26. Expected Viscosity After COVID-19 Vaccination, Hyperviscosity and Previous COVID-19.
Joob B; Wiwanitkit V
Clin Appl Thromb Hemost; 2021; 27():10760296211020833. PubMed ID: 34142570
[No Abstract] [Full Text] [Related]
27. Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma.
Avivi I; Balaban R; Shragai T; Sheffer G; Morales M; Aharon A; Lowenton-Spier N; Trestman S; Perry C; Benyamini N; Mittelman M; Tabib Y; Bar Lev T; Zavaro M; Herishanu Y; Luttwak E; Cohen YC
Br J Haematol; 2021 Oct; 195(2):186-193. PubMed ID: 34196388
[TBL] [Abstract][Full Text] [Related]
28. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases.
Simon D; Tascilar K; Fagni F; Krönke G; Kleyer A; Meder C; Atreya R; Leppkes M; Kremer AE; Ramming A; Pachowsky ML; Schuch F; Ronneberger M; Kleinert S; Hueber AJ; Manger K; Manger B; Berking C; Sticherling M; Neurath MF; Schett G
Ann Rheum Dis; 2021 Oct; 80(10):1312-1316. PubMed ID: 33958324
[TBL] [Abstract][Full Text] [Related]
29. SARS-CoV-2 Antibody Response in Persons with Past Natural Infection.
Anichini G; Terrosi C; Gandolfo C; Gori Savellini G; Fabrizi S; Miceli GB; Cusi MG
N Engl J Med; 2021 Jul; 385(1):90-92. PubMed ID: 33852796
[No Abstract] [Full Text] [Related]
30. A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2.
Majdoubi A; Michalski C; O'Connell SE; Dada S; Narpala S; Gelinas J; Mehta D; Cheung C; Winkler DF; Basappa M; Liu AC; Görges M; Barakauskas VE; Irvine M; Mehalko J; Esposito D; Sekirov I; Jassem AN; Goldfarb DM; Pelech S; Douek DC; McDermott AB; Lavoie PM
JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33720905
[TBL] [Abstract][Full Text] [Related]
31. Neutralizing SARS-CoV-2.
Poeschla E
Elife; 2020 Dec; 9():. PubMed ID: 33320086
[TBL] [Abstract][Full Text] [Related]
32. Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results.
Lombardi A; Bozzi G; Ungaro R; Villa S; Castelli V; Mangioni D; Muscatello A; Gori A; Bandera A
Front Immunol; 2021; 12():657711. PubMed ID: 33777055
[No Abstract] [Full Text] [Related]
33. Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls.
Bitoun S; Henry J; Vauloup-Fellous C; Dib N; Belkhir R; Mouna L; Joly C; Desjardins D; Bitu M; Le Grand R; Seror R; Roque Afonso AM; Mariette X
J Hematol Oncol; 2021 Oct; 14(1):166. PubMed ID: 34645504
[TBL] [Abstract][Full Text] [Related]
34. A Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2.
Han X; Wang Y; Li S; Hu C; Li T; Gu C; Wang K; Shen M; Wang J; Hu J; Wu R; Mu S; Gong F; Chen Q; Gao F; Huang J; Long Y; Luo F; Song S; Long S; Hao Y; Li L; Wu Y; Xu W; Cai X; Gao Q; Zhang G; He C; Deng K; Du L; Nai Y; Wang W; Xie Y; Qu D; Huang A; Tang N; Jin A
Front Immunol; 2021; 12():653189. PubMed ID: 33828563
[TBL] [Abstract][Full Text] [Related]
35. Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients.
Luchsinger LL; Ransegnola BP; Jin DK; Muecksch F; Weisblum Y; Bao W; George PJ; Rodriguez M; Tricoche N; Schmidt F; Gao C; Jawahar S; Pal M; Schnall E; Zhang H; Strauss D; Yazdanbakhsh K; Hillyer CD; Bieniasz PD; Hatziioannou T
J Clin Microbiol; 2020 Nov; 58(12):. PubMed ID: 32917729
[TBL] [Abstract][Full Text] [Related]
36. Dynamics of neutralizing antibody responses to SARS-CoV-2 in patients with COVID-19: an observational study.
Xu X; Nie S; Wang Y; Long Q; Zhu H; Zhang X; Sun J; Zeng Q; Zhao J; Liu L; Li L; Huang A; Hou J; Hou FF
Signal Transduct Target Ther; 2021 May; 6(1):197. PubMed ID: 34006847
[TBL] [Abstract][Full Text] [Related]
37. A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain.
Niu L; Wittrock KN; Clabaugh GC; Srivastava V; Cho MW
Front Immunol; 2021; 12():647934. PubMed ID: 33995366
[TBL] [Abstract][Full Text] [Related]
38. Examining the immunological responses to COVID-19 vaccination in multiple myeloma patients: a systematic review and meta-analysis.
Harandi H; Fallahtafti P; Karimi A; Hashemi SM; Mahalleh M; Ashouri M; Salehi MA; Hoveidaei A
BMC Geriatr; 2024 May; 24(1):411. PubMed ID: 38720296
[TBL] [Abstract][Full Text] [Related]
39. SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors.
Frieman M; Harris AD; Herati RS; Krammer F; Mantovani A; Rescigno M; Sajadi MM; Simon V
EBioMedicine; 2021 Jun; 68():103401. PubMed ID: 34051441
[No Abstract] [Full Text] [Related]
40. Serologic Response to Vaccine for COVID-19 in Patients with Hematologic Malignancy: A Prospective Cohort Study.
Hillyer A; Quint A; Ghassemian A; Joh-Carnella N; Knauer MJ; Dawd D; Lazo-Langner A; Mangel J; Lam S; Abdoh H; Xenocostas A; Deotare U; Saini L; Foster C; Louzada M; Ho J; Chin-Yee I; Phua CW
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):305-315. PubMed ID: 38336492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
